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Abstract
In order to investigate whether DNA methylation marks could contribute to the incomplete penetrance of the FV Leiden
mutation, a major genetic risk factor for venous thrombosis (VT), we measured genome-wide DNA methylation levels in
peripheral blood samples of 98 VT patients carrying the mutation and 251 VT patients without the mutation using the
dedicated Illumina HumanMethylation450 array. The genome-wide analysis of 388,120 CpG probes identified three sites
mapping to the SLC19A2 locus whose DNA methylation levels differed significantly (p,3 1028) between carriers and non-
carriers. The three sites replicated (p,2 1027) in an independent sample of 214 individuals from five large families
ascertained on VT and FV Leiden mutation among which 53 were carriers and 161 were non-carriers of the mutation. In
both studies, these three CpG sites were also associated (2.33 10211,p,3.02 1024) with biomarkers of the Protein C
pathway known to be influenced by the FV Leiden mutation. A comprehensive linkage disequilibrium (LD) analysis of the
whole locus revealed that the original associations were due to LD between the FV Leiden mutation and a block of single
nucleotide polymorphisms (SNP) located in SLC19A2. After adjusting for this block of SNPs, the FV Leiden mutation was no
longer associated with any CpG site (p.0.05). In conclusion, our work clearly illustrates some promises and pitfalls of DNA
methylation investigations on peripheral blood DNA in large epidemiological cohorts. DNA methylation levels at SLC19A2
are influenced by SNPs in LD with FV Leiden, but these DNA methylation marks do not explain the incomplete penetrance
of the FV Leiden mutation.
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Introduction
Venous thrombosis (VT) is a common complex disease
characterized by a sibling relative risk of ,3 [1] and heritability
estimates ranging from 30% to 60% [2,3]. Contrary to other
complex diseases, few new VT susceptibility genes were discovered
by the recent waves of Genome-Wide Association Studies (GWAS)
[4]. Established VT-associated genes collectively explain only
about 5% of the disease heritability [2] and family history of VT
remains an important risk factor despite adjustment for known
variants [5,6]. In addition, marked clinical variability is observed
even in affected individuals from the same family and carrying the
same mutation [6]. In particular, the penetrance of the FV Leiden
mutation (i.e. F5 R506Q or rs6025T/C), one of the major VT
genetic risk factors present in about 5% of the general population,
is quite low, only 10% of heterozygotes and 80% of homozygotes
develop VT in their lifetime, with varying severity among affected
individuals. These observations suggest that additional genetic and
non-genetic factors contribute to the incomplete penetrance of FV
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Leiden and the clinical heterogeneity VT, as well as idiopathic
VT.
Several lines of evidence support the role of DNA methylation
marks as contributing factors in complex human diseases,
including thrombosis-related disorders [7–11]. For example,
quantitative risk factors for VT such as body-mass-index [12]
and levels of von Willebrand factor [13], Factor VIII [14], and
homocysteine [15] have been associated with DNA methylation
marks. Further, lifestyle and environmental VT risk factors, such
as smoking and air pollution, have been associated with
methylation levels in genes relevant to VT pathophysiological
mechanisms [16–18]. Until recently, such investigations were
restricted to experimental models or small study samples, and
restricted to candidate genomic regions.
The recent enthusiasm for agnostic investigations of methylation
marks in peripheral blood DNA as a mean to investigate complex
disease etiology and to generate novel mechanistic hypotheses is
justified [19–21]. First,genome-wide methylation arrays, such as
the Illumina HumanMethylation450 bead array, are now widely
recognized as robust and efficient tools for epidemiological studies
aiming at identifying methylation marks at CpG sites associated
with environmental and genetic risk factors [12,22,23]. Second,
biobanked peripheral blood DNA has been shown to be a robust
and practical model for epidemiological epigenetic investigations
[12,24–26]. Third, evidence of peripheral blood DNA methylation
marks as surrogates for methylation marks at other disease
relevant tissues and cell types are increasingly emerging
[12,23,24]. As whole blood DNA methylation levels reflect the
average level resulting from the epigenetic state at different cell
types, the identification of DNA methylation marks in peripheral
blood cells may point out to novel biological mechanisms that
subsequently can be validated in the principal effector cell types
where stronger associations are expected [12]. Finally, and specific
to this study, DNA from peripheral blood originates mainly from
leukocytes, which are key effector cells for both coagulation and
inflammation, the two principal pathophysiological mechanisms
underlying VT.
In the current work, we hypothesized that DNA methylation
marks contribute to the incomplete penetrance of the FV Leiden
mutation. We undertook a DNA methylome-wide association scan
(MWAS, sometimes referred to as EWAS which stands for
Epigenome-Wide Association Scan) to identify DNA methylation
changes in relation to the presence/absence of the F5 rs6025
mutation in 349 (98/251) MARTHAVT patients. Main findings
were replicated in an independent study of 214 (53/161)
individuals, processed with the same Illumina array.
Material and Methods
Ethics Statement
For MARTHA, ethics approval was obtained from the
"De´partement sante´ de la direction ge´ne´rale de la recherche et
de l’innovation du ministe`re" (Projects DC: 2008-880 & 09.576).
For the F5L-families study, ethics approval was obtained from
the Ottawa Hospital and the University of Toronto ethics boards.
All subjects in both studies provided written informed consent in
accordance with the Declaration of Helsinki.
Study populations
Discovery study sample. The MARTHA study is a
collection of 1,542 patients with VT recruited from the
Thrombophilia centre of La Timone hospital (Marseille, France)
[27–30]. All subjects had a documented history of VT, were free of
chronic conditions, and were free of inherited thrombophilia
including: anti-thrombin, protein C and protein S deficiencies and
homozygosity for the Factor V Leiden and Factor II G20210A
mutations. For the current project, 349 MARTHA patients were
randomly selected for DNA methylation analysis.
Replication study sample. The family study is composed of
five extended French-Canadian pedigrees, totaling 255 relatives,
ascertained at the Thrombosis Clinic of the Ottawa Hospital
through single probands with idiopathic VT and heterozygote for
the Factor V Leiden mutation. Probands were free of acquired VT
risk factors such as cancer, myeloproliferative disease, pregnancy,
puerperium, prolonged immobilization, trauma, surgery and
antiphospholipid syndrome, and were free of inherited thrombo-
philia (see above). A detailed description of this study can be found
in [27]. Only 218 family members for whom DNA was still
available were included in the current work.
Genome wide DNA methylation assay
Genomic DNA was isolated from peripheral blood cells using an
adaptation of the method proposed by [31]. For each sample, 1 mg
genomic DNA was bisulphite converted using the Qiagen EpiTect
96 Bisulfite Kit. Then, 200 ng of bisulfite-converted DNA at
50 ng/ml was independently amplified, labeled, and hybridized to
Infinium HumanMethylation450 BeadChip microarrays [25] and
scanned with default settings using the Illumina iScan. This
Illumina array covers 99% of RefSeq genes and surveys the DNA
methylation levels at 482,421 CpG sites, with an average of 17
CpG sites per gene region. The discovery and replication samples
were processed simultaneously at The Center for Applied
Genomics (TCAG, Toronto, Canada).
Quality controls and normalization procedures
From the 485,577 probes available on the Illumina array, we
excluded from further analyses probes that measured single
nucleotide polymorphisms (n = 65), that are either cross-reactive
(n = 30,969) or polymorphic at the targeted CpG site (n = 66,877)
[32,33]. Of note, 4,464 probes shared the two last features.
DNA methylation data were expressed as a b-value, a continuous
variable over the [0–1] interval, representing the percentage of
methylation of a given CpG site [34]. Methylation values were
corrected for background by use of the Noob method implemented in
the "methylumi" package [35], for dye bias following the manufac-
turer’s recommendation (http://support.illumina.com/downloads/
genomestudio_m_module_v18_ug_%2811319130_b%29.ilmn) and
normalized for design type bias according to the SWAN method [36]
implemented in the minfi R package [37].
Quality control and normalization were done simultaneously on
the MARTHA and F5L-families datasets. Probes (n = 4,010) with
a detection p-value (as described in the "minfi" package) greater
than 0.05 in more than 5% of the total processed samples were
then excluded from further analyses. Principal components
analysis was carried out on probe data to detect outliers and four
F5L-families individuals were then excluded. This led to a final
selection of 388,120 probes (among which 1,289 tagged for CpH
sites) that were tested for association with the presence/absence of
the FV Leiden mutation-tagging rs6025-C allele.
Biological measurements
In MARTHA, we used the Agkistrodon contortrix venom
(ACV) test as a quantitative biomarker of the protein C pathway.
The ACV test was expressed as a normalized ACV value (ACVn)
as described in [30]. The ACVn ratio was available in 260
MARTHA patients with DNA methylation measurements. A
complete blood count, including white blood cell types (neutro-
phils, lymphocytes, monocytes, eosinophils, and basophils), was
FV Leiden Mutation and Whole Blood DNA Methylation
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determined by ADVIA 120 Hematology System (Siemens
Healthcare Diagnostics, Deerfield, IL).
In F5L-families, activated protein C resistance (APCR) levels
were determined in 208 individuals using the APC-aPTT assay.
The results of the test are expressed as the APC-sensitivity ratio,
which is the quotient of the activated partial thromboplastin time
(aPTT) of the plasma sample with and without exogenous APC
[38].
Genotyping
MARTHA patients were genotyped with the Illumina Human
610/660W-Quad beadchips [28]. Autosomal SNPs that satisfied
quality control criteria (n = 481,002) [39] were then used for
imputing SNPs from the 1000 Genomes 2012-02-14 release
reference dataset. Imputation was performed by use of MACH
(v1.0.18.c) software [40]. All SNPs with acceptable imputation
quality (r2.0.3) [41], minor allele frequency.0.01 and mapping
to the chromosome 1 169101258–169555769 locus were tested for
association with SLC19A2 probes.
The F5L-families study was genotyped with the Illumina 660W-
Quad beadchip. Detailed description of the quality control
procedure is available in [28].
Statistical Analysis
Discovery MWAS. Because methylation b-values are often
not normally distributed, exhibiting bi-modality, right-, or left-
tailed skewed distributions, our discovery MWAS was performed
using a logistic regression model with carrier status (yes or no) as
the outcome and the b-values as covariates. Any methylation
probes that satisfied the Bonferroni threshold of 1.2961027
(,0.05/388,120) were selected and their distribution was assessed
(Figure S1). For uni-modal probes, a linear regression model was
also applied with b-values as the outcome and carrier status as the
covariate to assess the consistency of the MWAS results and to
provide an estimate of the effect of the rs6025 variant on the DNA
Table 1. Characteristics of the studied populations.
MARTHA F5L-famiiles
N=349 N=214
Mean age in yrs 6 SD 43.8614.1 39.6616.7
Males/Females 75/274 101/113
VT patients (%) 349 (100%) 11 (5.1%)
Heterozygote carriers of the F5 rs6025 98 53
ACVn ratio(1) 0.8960.38 NA
F5 rs6025 carriers 0.5260.10 NA
Non-carriers 1.0960.32 NA
APCR ratio (2) NA 2.5660.67
F5 rs6025 carriers NA 1.6760.19
Non-carriers NA 2.8660.49
(1) In MARTHA, ACVn ratio was significantly (p = 1.63 10238) decreased in F5 rs6025 carriers compared to non-carriers.
(2) In families, APCR ratio was significantly (p = 9.98 10247) decreased in F5 rs6205 carriers compared to non-carriers.
doi:10.1371/journal.pone.0108087.t001
Figure 1. Manhattan plot of the MWAS results at 388,120 CpG sites.
doi:10.1371/journal.pone.0108087.g001
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methylation b-value. A linear regression model with M-trans-
formed values [42,43] instead of b-values as outcome was also
applied to provide further statistical support to the obtained results
(Table S1). Analyses were adjusted for age, sex, batch and chip
effects [44]. Because DNA methylation levels measured in
peripheral blood DNA reflect the average level of DNA
methylation in different cell types including lymphocytes, neutro-
phils, basophils and eosinophils, all analyses were also adjusted for
cell type composition to avoid any contamination bias [45–47].
For this, we used specific biological counts of lymphocytes,
monocytes, neutrophils, eosinophils and basophils available for all
MARTHA samples to characterize cell type composition.
Replication study. In the F5L-families study, association of
selected probes with rs6025 was assessed using the linear model
mentioned above, after having checked for the uni-modality of the
data distribution (Figure S1). In order to handle correlations
between family data, a linear mixed regression model as
implemented in the NMLE R package (http://cran.r-project.
org/web/packages/nlme/) was employed where the family
variable was defined as a random effect. Analyses were adjusted
for age, sex, batch, chip and cell type composition. As specific cell
type counts were not available in the family study, adjustment for
cell type composition was handled by the method described in
[48,49]. The Bonferroni corrected threshold of 0.0167 ( = 0.05/3)
was used for declaring replication.
Further analyses. Association of selected probes with
quantitative biomarkers was tested using a linear (mixed in F5L-
families) model where log-transformed biomarker values were used
as the outcome and the methylation b-values as covariates. Models
were adjusted by the same covariates as described above.
The association of imputed SNPs with methylation b-values was
tested by entering the allele dosage of the imputed SNP as a
covariate in a linear regression model with b-values as the
outcome. The allele dosage is a real number ranging from 0 to 2
corresponding to the expected number of minor alleles computed
from the posterior probabilities of possible imputed genotypes.
To get more power for detecting CpG sites variability associated
with the F5 rs6025, we finally performed a combined analysis of
both MARTHA and F5L-families studies. For this part, linear
regression analyses (mixed linear model in F5L-families) were
conducted for each CpG b-value with the rs6025 as covariate
while adjusting for the same variables as indicated above.
Regression coefficients associated with the rs6025 were then
combined into a random-effect meta-analysis using the GWAMA
program [50].
Results
Brief characteristics of the two studied populations are given in
Table 1. To support the validity of the discovery MARTHA DNA
methylation dataset, we investigated two previously reported
robust associations with DNA methylation marks, the association
of smoking with decreased methylation levels at F2RL3 CpG
cg03636183 [16,22] and the association of rs713586 with
DNAJC27/ADCY3 CpG cg01884057 [51]. Consistent and strong
significant associations were observed in MARTHA. Current
smokers exhibited lower levels of methylation at cg03636183
compared to non-smokers and former smokers (p = 1.13610229)
(Figure S2). The rs713586-T allele was associated with decreased
methylation b-values at cg01884057 in a fairly additive manner
(p = 7.38610268) (Figure S3).
A Manhattan plot of the MWAS results is shown in Figure 1.
Three CpG sites, all mapping the SLC19A2 gene region, were
associated with rs6025 at the genome-wide significant threshold of
1.2961027 (,0.05/388,120). DNA methylation levels at these
sites, cg16548605 (p = 3.61610211), cg04083076 (p = 2.82610210)
and cg09671955 (p = 2.6661028), were decreased in carriers of
the rs6025-C allele compared to non-carriers (Table 2, Figure S4).
Table 2. Association(1) of SLC19A2CpG sites with rs6025 (FV Leiden mutation) in the discovery and replication studies.
Discovery MARTHA study Replication F5L-families study
Non-Carriers
(N=251)
Carriers
(N=98)
Association Test p-
value(2)
Non-Carriers
(N=161)
Carriers
(N=53)
Association Test p-
value(2)
cg16548605 0.93 (0.02) 0.89 (0.03) 1.90 10229 0.93 (0.02) 0.90 (0.03) 6.58 10214
cg04083076 0.73 (0.06) 0.64 (0.06) 5.73 10222 0.74 (0.06) 0.67 (0.09) 1.19 10210
cg09671955 0.53 (0.06) 0.48 (0.07) 3.49 10212 0.55 (0.07) 0.50 (0.07) 5.62 1027
(1) Association is expressed as methylation b-value mean (SE) in carriers and non-carriers.
(2) Reported p-values were those derived from a linear regression model where the probe methylation level was the outcome and the carrier status the covariate, while
adjusting for age, sex, batch, chip and cell type composition.
doi:10.1371/journal.pone.0108087.t002
Table 3. Association(1) of SLC19A2 CpG sites with ACVn (MARTHA) and APCR (F5L-families) phenotypes.
MARTHA study (N=260) F5L-families study (N=208)
raw(2) Adjusted for rs6025 raw(2) Adjusted for rs6025
cg16548605 46.9 (32.6–61.1) p = 8.14 10210 21.2 (214–11.7) p = 0.86 58.1 (44–72.1) p = 1.11 10213 13.6 (3.1–24.1) p = 0.01
cg04083076 18.1 (11.5–24.7) p = 2.12 1027 23.1 (28.8–2.50) p = 0.28 21.9 (15.1–28.7) p = 2.13 1029 3.9 (20.8–8.5) p = 0.10
cg09671955 15.1 (7.4–22.9) p = 1.7 1024 21.9 (27.8–4.0) p = 0.53 14.4 (7.3–21.4) p = 1.02 1024 21.3 (24.6–4.1) p = 0.90
(1) Association is expressed as % change in phenotype (95% Confidence Interval) for every 0.1 unit increase in methylation b-value.
(2) Analysis were adjusted for age, sex, batch, chip and cell type composition.
doi:10.1371/journal.pone.0108087.t003
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Of note, the strongest association observed with any F5 CpG site
was p = 0.045 for cg16054275.
These three CpG probes were tested for replication in 214
related individuals from the F5L Thrombophilia French-Canadian
Pedigree study [27,28], referred thereafter to as the F5L-families
study. In this independent study, all three SLC19A2 probes also
exhibited lower DNA methylation levels in carriers (n = 53)
compared to in non-carriers (n = 161) of the rs6025-C allele
(Table 2; Figure S5).
To further validate these results, using a linear model, we
assessed the association of the 3 SLC19A2 probes with quantita-
tive biomarkers of the Protein C pathway known to be under the
strong influence of rs6025: the Agkistrodon contortrix venom test
(ACVn) [30,52] in the discovery MARTHA population and the
activated protein C resistance (APCR) test [53] in the replication
family study. In both studies, these biomarkers demonstrated
decreased levels in carriers of the F5 rs6025-C allele compared to
non-carriers (Table 1). The three SLC19A2 CpG sites were
significantly associated with the two biomarkers, with all p-
values,1023 (Table 3). For example, every 0.1 unit increase in the
methylation b-value at cg16548605 was associated with a 46.9%
(95% confidence interval: 32.6%–61.1%) higher ACVn value in
the MARTHA population and with a 50.0% (95%CI: 36.3%–
63.7%) higher APCR value in the F5L-families. After adjusting for
rs6025, these associations completely vanished, with all p-values
.0.01 (Table 3).
Because the SLC19A2 gene maps to chromosome 1q23.3 in the
vicinity of the F5 gene, a locus known to exhibit strong linkage
disequilibrium (LD) over a large genomic distance of ,460 Kb
[39] (Figure S6), one cannot rule out the possibility that the
associations between rs6025 and methylation at SLC19A2 probes
were due to other SNPs in LD with rs6025. We therefore
examined the association of the methylation levels of the three
SLC19A2 probes with 3,213 SNPs at this locus using genome-
wide SNP data available in the MARTHA study. Results of these
association analyses, where DNA methylation levels were the
outcome and the SNPs the predictors, are illustrated in Figure 2.
The strongest association for cg16548605 was observed with
rs970740 (p = 1.61610266) where the minor C allele was
associated with decreased cg16548605 methylation levels (Table 4)
(regression coefficient for adjusted allele effect b=20.049
60.0022). The same pattern of associations was observed in the
F5L-families study (Table 4). The C allele was also associated with
decreased ACVn values (b= -0.41560.043, p = 3.20610218)
(Table 5). Interestingly, in a joint model where both rs970740
and rs6025 were used as covariates for predicting cg16548605
variability, the effect of rs970740 was highly significant
(p = 1.05610238) but that of rs6025 was not (p = 0.90). Conversely,
in a similar joint model for predicting ACVn levels, only the effect
of rs6025 was significant (p = 1.65610220) while the effect of
rs970740 completely vanished (p = 0.79). Rs970740 lies in the
upstream SLC19A2/downstream F5 region and is in moderate
LD (r2 = 0.65) with the F5 rs6025. Similar patterns were observed
Figure 2. Region Association plot of the association between chromosome 1q23.3 SNPs and cg16548605 CpG site variability in the
MARTHA study.
doi:10.1371/journal.pone.0108087.g002
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for the other SLC19A2 cg04083076 and cg09671955 CpG sites
(data not shown).
These results demonstrate that two independent phenomena act
at this locus: an effect of rs970740 (or its proxies) on the variability of
SLC19A2 methylation levels and the effect of F5 rs6025 on the
ACVn biomarker. The presence of LD between rs970740 and the
F5 rs6025 mutation confounds the associations between methylation
at SLC19A2 sites and both the F5 rs6025 and the ACVn biomarker.
To improve statistical power and increase opportunity to detect
smaller effect sizes of additional CpG sites and F5 rs6025
associations, we combined the discovery and replication study
samples into a meta-analysis. An additional CpG probe
(cg26009832) mapping the SLC19A2/F5 locus reached genome-
wide significance (p = 1.42 1028).
Discussion
The starting hypothesis of this work was that DNA methylation
marks associate with the F5 rs6025 mutation and contribute to the
incomplete penetrance of this strong genetic risk factor for VT.
Thus, we undertook the first MWAS of the F5 rs6025 in a large
sample of 349 individuals and replicated the findings in an
independent sample of 214 related subjects. We identified and
replicated three CpG sites exhibiting a genome-wide significant
difference in methylation levels in carriers and non-carriers of the
mutation. These CpG sites were also strongly associated with the
plasma variability of quantitative biomarkers influenced by the F5
rs6025. However, when we integrated our MWAS and GWAS
data, the observed associations between methylation levels at three
CpG sites in SLC19A2 and F5 rs6025 were in fact due to LD
between the rs6025 and SNPs located in SLC19A2.
We observed strong statistical evidence for association between
the SLC19A2 promoter rs970740 SNP (or any SNP in strong LD
with it) and three identified SLC19A2 CpG sites, independently of
F5 rs6025. According to public database, including 1000
Genomes, none of the probes measuring these three CpG sites
are polymorphic and the rs970740 does not map to a CpG island.
This strongly suggests the existence of variant(s) influencing the
variability of DNA methylation levels at the SLC19A2 gene. How
the rs970740 T/C genetic variation (or any linked SNP) affects
SLC19A2 DNA methylation remains an open question. This
could be through the creation of a transcription factor binding site,
the modification of the local CpG sites distribution, or more
complex phenomena [54–59]. The SLC19A2 gene codes for a
thiamine transporter protein that has been associated with human
anemia syndrome [60–62]. Our results suggest that genetically
determined DNA methylation sensitive mechanisms are involved
in this disease susceptibility.
Several conclusions could be drawn from this work. First, three
identified CpG sites were found to be strongly associated with the
plasma variability of two quantitative biomarkers of the coagula-
tion cascade, supporting the potential of genome-wide DNA
methylation data to identify epigenetic marks associated with
biological phenotypes involved in thrombotic disorders. Nonethe-
less, this works highlights the need for careful analyses of
associations between genetic variants, biological phenotypes, and
methylation at CpG sites to avoid false inference on functional
variant(s), in particular due to LD extending over large genomic
distances. Integrating MWAS, GWAS and biological data from
the same individuals, as illustrated here, is key to elucidating these
relationships. Second, if such cautions are taken, DNA methyla-
tion data can help to dissect the functional mechanisms associated
with known disease-causing SNPs.T
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Several limitations must be acknowledged. First, the design of
our study may not be optimal. As we did not have access to a case-
control study for VT with genome-wide DNA methylation data,
we adopted a ’case-only’ approach for our discovery stage. Such
approach has been shown to be a valid alternative to detect gene6
environment or gene6 gene interactions [63,64]. We here used
this strategy with the aim of identifying epigenetic factors that
interact with the FV Leiden mutation to modulate the risk of VT.
Since, in our replication study, 45 carriers were VT patients and
the remaining 8 carriers were healthy individuals, we also looked
into this dataset for specific methylation patterns associated with
VT but the low sample size precludes from identifying any
significant association (data not shown).
Second, because homozygosity for FV Leiden mutation was an
exclusion criteria for the MARTHA study and no homozygote was
observed in the F5L-families, our analysis only included hetero-
zygous carriers which may have reduced our power to identify
CpG sites under the strong influence of the mutation.
Third, while extremely dense, the used Illumina array does not
cover all sites of the genome that could be subject to DNA
methylation, we cannot exclude that some relevant methylation
association has been missed.
Fourth, the sample size of our discovery study was large enough
to detect, at the genome-wide level of 1.29 1027, a 0.05 increase in
the methylation b-value. Whether an increase of smaller
magnitude in DNA methylation marks detected in whole blood
could be biologically relevant remains an open question. Whole
blood DNA methylation levels reflect the average levels resulting
from the epigenetic state at different white blood cells. Therefore,
the cell subtype and tissue specific methylation marks would show
a weaker effect in whole blood compared to levels that could be
measured in thrombosis-relevant effector cells (e.g. monocytes,
endothelial cells, hepatocytes). This phenomenon was recently
observed and discussed for other cardiovascular-related pheno-
types [12,65]. Thus, we cannot rule out the possibility that a
stronger influence of F5 rs6025on DNA methylation levels exists
in specific cell types or tissues, such as the liver where F5 is mainly
synthetized.
Last, we observed evidence that SLC19A2, with genetically
determined DNA methylation levels, is a methylation quantitative
trait locus (mQTL). However, as we did not have access to gene
expression data, we were not able to assess whether the observed
genetic influence on SLC19A2 DNA methylation levels is followed
by a direct impact on SLC19A2 expression. Further epi-mapping
at this locus would be of great interest.
In conclusion, our work does not support the existence of DNA
methylation marks that could explain the incomplete penetrance
of the F5 rs6025. The incomplete penetrance could be the result of
complex haplotype effects at the F5 locus, or interaction at this
locus with other genetic or environmental exposures; such
investigations would require alternative study designs and much
larger sample sizes to detect effects.
This work does, however, illustrate the promises and pitfalls of
MWAS on peripheral blood DNA in large epidemiological studies,
and suggests that the anemia-associated SLC19A2 gene is a
mQTL.
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Table 5. Association of rs970740 and rs6025 with SLC19A2 cg16548605 CpG and ACVn levels in the MARTHA study.
cg16548605 ACVn (log)
Univariate analysis (1)
rs970740 b=20.049 (0.0022) p = 1.61 10266 b=20.415 (0.043) p = 3.20 10218
rs6025 b=20.044 (0.0035) p = 1.9 10229 b=20.653 (0.042) p = 3.58 10237
Joint analysis (2)
rs970740 b=20.050 (0.0033) p = 1.05 10238 b=20.014 (0.052) p = 0.79
rs6025 b= 0.001 (0.004) p = 0.90 b=20.641 (0.062) p = 1.65 10220
Association is expressed as the additive effect of the minor alleles on the variability of cg16548605 and log ACVn (95% Confidence Interval) adjusted for age, sex, batch,
chip and cell type composition. In the univariate analysis(1), one SNP at a time is used as a covariate for predicting the phenotype. In the joint analysis (2), both SNPs are
simultaneously introduced as predictors in the linear regression models.
doi:10.1371/journal.pone.0108087.t005
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